Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Medpace (MEDP) stock in plain English

Free brief · no signupStart here
MEDPPublished Nov 8, 2026
Medpace Holdings Inc
Healthcare · Diagnostics & Research
Manages Phase I through IV clinical trials for biotechnology and pharmaceutical developers. Operates central laboratories and specialized clinics to collect and analyze patient trial data.
Assets:
Cincinnati headquartersCentralized corporate and laboratory campus in Ohio
5,400+ staffGlobal workforce of medical and operational specialists
4 central laboratoriesCore testing facilities in the US, Europe, and Asia
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

70
OPS ScoreOperating finances
Latest quote
-1.99%$633.98
$17.73B
35.2×
$2.84B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 08, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was MEDP. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Medpace (MEDP) do?

Medpace Holdings Inc (MEDP) is a U.S.-listed company in Healthcare (Diagnostics & Research). What it does: Manages Phase I through IV clinical trials for biotechnology and pharmaceutical developers. Operates central laboratories and specialized clinics to collect and analyze patient trial data. It manages clinical drug trials primarily for small and mid-sized biotechnology firms using an internal staff model. It is worth $17.73B on the market and sold $2.84B over the last year.

Market cap
$17.73B
P/E ratio
35.2×
Annual sales
$2.84B
Sector
Healthcare
Industry
Diagnostics & Research
Brief updated
Nov 08, 2026

MEDP’s flags, in plain English

Each flag is a number from Medpace’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 08, 2026.

Earns Its Keep

Earns 117.9% a year on shareholders' money. The company earns a healthy return on the money its shareholders have put in.

Capital Works Hard

Earns 70.8% a year on the money it invests in the business. The money in the business, from shareholders and lenders together, earns a strong return. That points to a company that picks its investments well.

Low debt

Low debt, only 29% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Runway Is Short

This year's bills are bigger than the cash and assets on hand to pay them. At its current rate of spending, its cash on hand covers only a limited stretch.

2 more green flags and 1 more risk note open with the free trial. Try it free for 7 days.

Questions about MEDP

How big is Medpace?

Medpace’s market cap is $17.73B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $2.84B: what customers paid the company over the last year, before any costs.

What is MEDP’s P/E ratio?

MEDP’s P/E ratio is 35.2×. Investors pay about 35.2 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with MEDP?

The company relies heavily on small and mid-sized biopharma clients that depend on external funding to finance their studies. That is one risk on Medpace’s card. Its first risk flag is Runway Is Short, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Medpace’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. MEDP’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card